

## OPEN CLINICAL TRIALS

Sponsor	NCT #	Protocol Title	Principal Investigator
DiaMedica	NCT05065216	Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDY2 Trial) Protocol Number: DM199-2021-001	Lance Lee, MD
BMS	NCT03766581	A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor X1a Inhibitor, for the Prevention of New Ischemic Stroke or New Silent Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Non-Hemorrhagic Stroke or Transient Ischemia Attack (TIA)	Lance Lee, MD
Cerapedics	NCT03438747	An Assessment of P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion with Instrumentation	Jared Ament, MD
TP Therapeutics	NCT03093116	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Mihran Shirinian, MD
PREMIA	NCT03012776	A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPSTM System	Jared Ament, MD
ImmunitoBio	NCT03520686	A Phase 2, Open-Label, Randomize Study of ALT-803, A Fusion Protein Activator of Natural Killer and T Cells, in Combination with Pembrolizumab vs Pmbrolizumab Alone as First-Line Treatment for Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC)	Mihran Shirinian, MD
ImmunitoBio	NCT03228667	QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination with Pembrolizumab or Nivolumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer who have Disease Progression Following an Initial Response to Treatment with PD-1 Checkpoint Inhibitor Therapy	Mihran Shirinian, MD
Doterra		Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ	Dennis Holmes, MD
Pfizer	NCT04672460	Pfizer / Pfizer / A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS	Mihran Shirinian, MD
Genentech	NCT04873362	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy	Mihran Shirinian, MD
Genentech	NCT03785678	A PHASE III, PROSPECTIVE, DOUBLE-BLIND RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THROMBOLYSIS IN IMAGING-ELIGIBLE, LATE-WINDOW PATIENTS TO ASSESS THE EFFICACY AND SAFETY OF TENECTEPLASE (TIMELESS)	Mikayel Grigoryan, MD
Novartis	NCT01958021	A Randomized Double-Blind, Placebo-Controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2 negative, advanced breast cancer who received no prior therapy for advanced disease	Boris Bagdasarian, DO
Pfizer	NCT03499353	A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE	Mihran Shirinian, MD
Pfizer	NCT04821622	TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER	Mihran Shirinian, MD
RADIUS	NCT03778931	Elaeestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)	Mihran Shirinian, MD
PROTECT IV	NCT04763200	Impella®-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial	Hambik Tankazyan, MD
PAREXEL Phase I Unit	NA	Services provided to outside research company	NA
CNS	NA	Services provided to outside research company	NA
New School Research	NA	Services provided to outside research company	NA

## PIPELINE

Sponsor	NCT #	Protocol Title	Principal Investigator
Caris Life Sciences	TBD	DINOSAur: Discovering novel cancer treatment options using a comprehensive NGS-based molecular testing panel in the community setting	Mihran Shirinian, MD
Galaxy Medical	TBD	CENTAURI Pulsed ELectric Field Effectiveness and Safety Trial for Indication of Ablation for Atrial Flutter	John McKenzie, MD
Veru MBC Phase II	NCT05065411	Veru V2000701: A Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treatment Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib	Mihran Shirinian, MD
Veru MBC Phase III	NCT04869943	Randomized Phase 3 Efficacy Evaluation of Enobosarm Monotherapy vs Control Treatment of AR+/ER+/HER2-MBC in Patients With AR Nuclei Staining ≥40% Who Has Shown Disease Progression on a Nonsteroidal AI Fulvestrant and CDK 4/6 Inhibitor.	Mihran Shirinian, MD
TP Therapeutics--MET mutation	NCT03993873	A Phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics, efficacy and anti-tumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1)	Mihran Shirinian, MD
TP Therapeutics--RET mutation	NCT04161391	A Phase 1/2 Study of TPX-0046, a Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations	Mihran Shirinian, MD
Pfizer	TBD	Multicenter, Randomized, Open-label Phase 3 Trial of ARV-471± GnRH analogue vs Investigator's Endocrine Treatment Choice ± GnRH analogue in Patients with Estrogen Receptor Positive, HER-2Negative Advanced Breast Cancer Whose Disease Progressed After One Prior CDK4/6 inhibitor plus Endocrine based Treatment for Advanced disease.	Mihran Shirinian, MD
Pfizer 1002	TBD	A randomized, multicenter, OPEN LABEL Phase 3 study of ARV-471 (Oral PROTAC) plus palbociclib versus AROMATASE INHIBITOR plus palbociclib for the treatment of Patients with Estrogen Receptor Positive, HER2 Negative breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.	Mihran Shirinian, MD

Guardant	TBD	Discovering novel cancer treatment options using a comprehensive NGS-based liquid molecular testing panel in the community setting. ("DINOSAur II")	Mihran Shirinian, MD
----------	-----	---	----------------------